Review
Oncology
Steven Nicolaides, Alex Boussioutas
Summary: Immunotherapy is an effective cancer treatment that activates the immune system to target and destroy cancer cells. However, the use of immune checkpoint inhibitors is often limited by immune-related adverse events. This review focuses on the management and emerging therapies for immune-related adverse events in the gastrointestinal system.
Review
Immunology
Blair S. Allais, Christopher J. Fay, Daniel Y. Kim, Yevgeniy R. Semenov, Nicole R. LeBoeuf
Summary: Decoupling toxicity from therapeutic effect is crucial in the field of cutaneous immune-related adverse events to immune checkpoint inhibitor therapy. Understanding the drivers of toxicity, tumor response, and resistance through population-level studies, cohort data, and cellular-level data is key. Increasing diagnostic specificity with consensus disease definitions has the potential to improve clinical care and research.
IMMUNOLOGICAL REVIEWS
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Kathleen M. Capaccione, Jacienta P. Valiplackal, Alice Huang, Tina Roa, Alana Fruauff, Connie Liou, Eleanor Kim, Sakshi Khurana, Mary Maher, Hong Ma, Pamela Ngyuen, Serena Mak, Shifali Dumeer, Sonali Lala, Belinda D'souza, Sherelle Laifer-Narin, Elise Desperito, Carrie Ruzal-Shapiro, Mary M. Salvatore
Summary: Cancer immunotherapies modulate the body's immune system to enhance immune response against cancer. However, immune-related adverse events (IRAEs) can result from these therapies, making it crucial for radiologists to recognize and manage them effectively.
ACADEMIC RADIOLOGY
(2022)
Article
Dermatology
Nga Nguyen, Guihong Wan, Pearl Ugwu-Dike, Nora A. Alexander, Neel Raval, Shijia Zhang, Ruple Jairath, Jordan Phillipps, Bonnie Leung, Katie Roster, Jayhyun Seo, Chenyue Lu, Kimberly Tang, Min Seok Choi, Mia S. DeSimone, Nicholas Theodosakis, Munachimso Amadife, Nevada Cox, Thomas K. Le, Feng Liu, Wenxin Chen, Xue Bai, Genevieve Boland, David Liu, Marc S. Hurlbert, Nicole LeBoeuf, Kerry L. Reynolds, Kun-Hsing Yu, Hensin Tsao, Maryam Asgari, Alexander Gusev, Shawn G. Kwatra, Yevgeniy R. Semenov
Summary: This study explores the impact of melanoma subtypes on the development of cutaneous immune-related adverse events (cirAEs) and survival outcomes in patients receiving immune checkpoint inhibitor (ICI) therapy for advanced melanoma. The results show that patients with acral melanoma have a lower risk of developing cirAEs compared to patients with nonacral cutaneous melanoma. Additionally, the presence of cirAEs is associated with better survival outcomes.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Oncology
Xiao-Tong Zhang, Nan Ge, Zi-Jian Xiang, Tao Liu
Summary: This study evaluated the incidence of cardiotoxicity related to immune checkpoint inhibitor (ICI) therapies for lung cancer. The results showed that single ICI did not increase the risk of cardiotoxicity compared to chemotherapy, while single ICI plus chemotherapy increased the risk of cardiotoxicity by 67% compared to chemotherapy alone. Combination immunotherapy did not increase the risk of cardiotoxicity compared to single ICI.
CANCER CELL INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Zhengqing Lei, Weihu Ma, Anfeng Si, Yuhua Zhang, Facai Yang, Qiushi Yu, Haolan Tang, Qianru Xiao, Jiahua Zhou, Kui Wang, Yufu Tang, Tao Han, Guowen Yin, Jinhong Chen, Xiufeng Liu, Hua Zhao, Decai Yu, Tao Luo, Qing Wang, Maolin Yan, Xianhai Mao, Jing Li, Kai Wang, Jingdong Li, Yongyi Zeng, Dequan Ding, Tingsong Chen, Xiaofeng Wu, Yongxiang Xia, Kang Wang, Weixing Guo, Guangyu Zhu, Shan Gao, Norbert Hueser, Wan Y. Lau, Tianqiang Song, Shuqun Cheng, Feng Shen, Zhangjun Cheng
Summary: This study compared the efficacy of different anti-PD-1 combination therapies as the first-line treatment for uICC. The results showed that ICI-chemo and ICI-target therapies had better survival outcomes and fewer adverse events compared to chemotherapy. ICI-target-chemo had similar efficacy to ICI-chemo but resulted in more adverse events.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang
Summary: This study investigated the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor therapy and reported the clinical features, management, and outcomes of ophthalmic irAEs. Medical records of 962 patients who received ICI therapy were retrospectively reviewed, and 248 patients (25.8%) experienced irAEs. The first-year incidences of total irAEs and ophthalmic irAEs were 23.5% and 1.1% respectively. The most common ICI received was pembrolizumab (38.8%).
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Heidar J. Albandar, Jacob Fuqua, Jasim M. Albandar, Salahuddin Safi, Samuel A. Merrill, Patrick C. Ma
Summary: This study did not identify significantly different survival outcomes among the Appalachian West Virginia adult cancer patients treated with ICI who developed irAE and had treatment reinitiated after interruption, when compared with those not reinitiated.
Review
Immunology
Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi
Summary: Cancer research has focused on prolonging the life of patients, and immune checkpoint inhibitors (ICIs) have shown good clinical efficacy but with severe adverse effects. Blood counts may serve as predictors of immune-related adverse events (irAEs) in cancer patients. This meta-analysis provides further evidence for the importance of blood counts in clinical practice.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Dermatology
Shijia Zhang, Kimberly Tang, Guihong Wan, Nga Nguyen, Chenyue Lu, Pearl Ugwu-Dike, Neel Raval, Jayhyun Seo, Nora A. Alexander, Ruple Jairath, Jordan Phillipps, Bonnie W. Leung, Kathleen Roster, Wenxin Chen, Leyre Zubiri, Genevieve Boland, Steven T. Chen, Hensin Tsao, Shadmehr Demehri, Nicole R. LeBoeuf, Kerry L. Reynolds, Kun-Hsing Yu, Alexander Gusev, Shawn G. Kwatra, Yevgeniy R. Semenov
Summary: This study investigated the association between cutaneous immune-related adverse events (cirAEs) and survival among immune checkpoint inhibitor (ICI) recipients. The results showed that the development of cirAEs was associated with improved survival, especially in patients with melanoma.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Oncology
Aneesha Haryal, Matthew J. Townsend, Vinitha Baskaran, Padmavathi Srivoleti, Anita Giobbie-Hurder, Jordan S. Sack, Raymond A. Isidro, Nicole R. LeBoeuf, Elizabeth Buchbinder, F. Stephen Hodi, Shilpa Grover
Summary: Gastrointestinal immune-related adverse events caused by immune checkpoint inhibitors (ICIs) often require interruption of cancer treatment. This study examined the clinical features and treatment outcomes of ICI gastritis. It was found that ICI gastritis can occur alone or more commonly with concurrent enteritis/colitis, with different clinical courses. Gastric biopsies are necessary to diagnose clinically significant cases with normal endoscopic appearance. Most patients with isolated gastritis can continue ICI therapy uninterrupted, but some may require glucocorticoids.
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Article
Oncology
Cong Zhou, Xiaojiao Cheng, Shuiping Tu
Summary: ICIs are revolutionizing cancer immunotherapy, with significant effects on melanoma and NSCLC. In the case of CRC, patients with high immunogenicity benefit from ICIs, while those with low immunogenicity do not. Ongoing clinical trials aim to improve response to ICIs in CRC patients through better selection and combination strategies.
Review
Oncology
Josefien W. Hommes, Rik J. Verheijden, Karijn P. M. Suijkerbuijk, Dorte Hamann
Summary: ICIs have improved cancer patient prognosis by blocking negative feedback mechanisms of the immune system, but can also lead to auto-immune toxicities. Despite numerous studies, no single biomarker has yet been proven to sufficiently predict the development of irAEs.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Carly C. Barron, Isabella Stefanova, Yevin Cha, Karam Elsolh, Arman Zereshkian, Nessma Gaafour, Elaine McWhirter
Summary: Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents. Little is known about chronic irAEs and they are felt to be rare.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Letter
Dermatology
Takeshi Fukumoto, Toshihiro Takai, Masanobu Sakaguchi, Masahiro Oka, Chikako Nishigori
JOURNAL OF DERMATOLOGY
(2018)
Article
Dermatology
Toshihiro Takai
Summary: Malignant melanoma is known for its diverse cellular morphologies, making it easily confused with non-melanocytic proliferations or infiltrates, especially when they coexist with true melanoma. This report presents a rare case of melanoma in situ with an underlying sarcoidal granuloma, mimicking dermal invasion of melanoma, and adds to the understanding of non-neoplastic lesions closely resembling melanoma.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Eriko Takayama, Akiko Yoshioka, Toshihiro Takai, Keisuke Goto
Summary: Muir-Torre syndrome is a hereditary condition characterized by sebaceous neoplasms and visceral tumors, with a common mechanism being a defect in mismatch repair genes. A 67-year-old woman with MLH1 mutation presented with keratoacanthomas and sebaceous neoplasms, showing loss of expression for MLH1 and PMS2 proteins in tumor cells nuclei. This suggests that the type of cutaneous tumor in Muir-Torre syndrome may be influenced by deficient mismatch repair proteins in the pilosebaceous unit.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Shin-ichi Ansai, Yoshihiro Umebayashi, Noriyuki Katsumata, Hiroshi Kato, Takafumi Kadono, Toshihiro Takai, Takeshi Namiki, Masahiro Nakagawa, Toshinori Soejima, Hiroshi Koga, Makoto Sugaya
Summary: This article presents the English version of the 2020 edition of the Japanese SCC guidelines, covering an overview of SCC and discussion of three clinical questions. The evaluation processes were strictly implemented according to the Grading of Recommendations, Assessment, Development, Evaluation system, with recommendations determined by a multidisciplinary expert panel.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Yasuhiro Mitsui, Kohei Ogawa, Kaori Koga, Keisuke Goto, Toshihiro Takai, Takashi Anan, Takaya Fukumoto, Hideo Asada
Summary: This study examined five cases of trichilemmal cyst with proteinaceous material (TCPM) and differentiated them from sweat duct/gland tumors. Histopathological findings and immunohistochemical expression were used to accurately diagnose TCPM.
JOURNAL OF CUTANEOUS PATHOLOGY
(2022)
Editorial Material
Dermatology
Toshihiro Takai, Tamotsu Sudo, Kazuyoshi Kajimoto, Keisuke Goto
JOURNAL OF CUTANEOUS PATHOLOGY
(2023)
Review
Dermatology
Nanako Tanaka, Shoko Nakatani, Chisato Yahiro, Toshihiro Takai
Summary: Radiation dermatitis is the most common adverse reaction of radiotherapy, and there have been reports of erythema multiforme-like rash associated with radiotherapy. We aimed to evaluate the potential association between radiotherapy and erythema multiforme-like rash in a larger sample of patients. Our study included 30 patients who developed erythema multiforme-like rash during or after radiotherapy, and in most cases, the rash was relieved by conservative management and radiotherapy could be continued. Radiotherapy should be considered as a potential trigger for erythema multiforme-like rash in cancer patients.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Keisuke Goto, Shusuke Yoshikawa, Toshihiro Takai, Kota Tachibana, Keiichiro Honma, Taiki Isei, Yoji Kukita, Takuma Oishi
Summary: This study found that melanoma with the BRAF V600K mutation mainly occurs on the scalp in elderly men. Histopathologically, it shows non-nested lentiginous intraepidermal growth and subtle solar elastosis, possibly accompanied by intradermal nevus. Immunohistochemistry analysis revealed frequent loss of p16 expression and limited immunoreactivity for PRAME. The tumor mutation burden was intermediate.
JOURNAL OF CUTANEOUS PATHOLOGY
(2023)